Immediate-Release Methylphenidate Formulations for ADHD

Available IR Methylphenidate Products

The American Academy of Child and Adolescent Psychiatry recommends standard methylphenidate tablets (Ritalin, Methylin) in 5 mg and 10 mg doses for breakthrough ADHD symptoms or when rapid onset of action is needed 1, 2
Methylphenidate IR tablets are available as brand names (Ritalin, Methylin) and generics in 5 mg and 10 mg strengths, with effects beginning within 30 minutes of ingestion 3, 4
Peak benefit occurs at 1-3 hours after administration, with effects lasting approximately 4 hours 4, 6

IR methylphenidate can be used for breakthrough symptom management, combined with sustained-release formulations to eliminate breakthrough ADHD symptoms during the day 4
The American Academy of Child and Adolescent Psychiatry suggests using IR formulations for initial titration, as they allow for more precise adjustments before converting to extended-release products 4
IR methylphenidate is preferred when rapid onset of action is needed within 30 minutes 2

IR methylphenidate produces higher peak plasma concentrations than sustained-release formulations, making it more effective for immediate symptom control 1, 2
The American Academy of Child and Adolescent Psychiatry notes that plasma levels do not correlate with clinical response and are not clinically useful for dose adjustment 1
Dosage must be titrated based on clinical response using teacher and parent rating scales rather than weight or plasma concentrations 1, 4

In Malaysia, MPH-IR 10 mg is available, with a maximum daily dose of 60 mg/day 3
In India, MPH-IR 5 mg and 10 mg tablets are available, with a maximum daily dose of 60 mg/day 3
In the Republic of Korea, MPH-IR 5 mg and 10 mg are available, with a maximum daily dose of 60 mg/day 3
In Taiwan, MPH-IR is designated as first-line medication for ADHD treatment 3